

Product Licence Number	Company Name (Consumer Healthcare (A Division of Roche Products Limited))	Product Name	Active Ingredients * As "Coated Paracetamol".	Indications (Non-Prescription Items)	Date of Authorisation
0201/0149	Schering-Plough Limited	Leucomax Injection 0.555 million IRU (50 mcg)	Molgramostim INN HSE 0.555 × 10 ⁶ (0.05 mg) (An unglycosylated rHu GM-CSF with isoleucine at position 100)	to moderate pain such as headache, migraine, neuralgia, backache, rheumatic and muscular pain, period pain and toothache. For the relief of the symptoms of coughs, colds and sore throats. For the reduction of fever in influenza. GSL	23rd October 1992
0201/0150	Schering-Plough Limited	Leucomax Injection 1.67 million IRU (150 mcg)	Molgramostim INN HSE 1.67 × 10 ⁶ (0.15 mg) (An unglycosylated rHu GM-CSF with isoleucine at position 100)		23rd October 1992
0201/0151	Schering-Plough Limited	Leucomax Injection 4.44 million IRU (400 mcg)	Molgramostim INN HSE 4.44 × 10 ⁶ (0.40 mg) (An unglycosylated rHu GM-CSF with isoleucine at position 100)		23rd October 1992
0201/0152	Schering-Plough Limited	Leucomax Injection 5.55 million IRU (500 mcg)	Molgramostim INN HSE 5.55 × 10 ⁶ (0.5 mg) (An unglycosylated rHu GM-CSF with isoleucine at position 100)		23rd October 1992
0201/0153	Schering-Plough Limited	Leucomax Injection 7.77 million IRU (700 mcg)	Molgramostim INN HSE 7.77 × 10 ⁶ (0.70 mg) (An unglycosylated rHu GM-CSF with isoleucine at position 100)		23rd October 1992
0201/0155	Schering-Plough Limited	Sterile Diluent for Intron A	None		15th October 1992
0201/0181	Schering-Plough Limited	Leucomax Injection 3.33 million IRU (300 mcg)	Molgramostim INN HSE 3.33 × 10 ⁶ (0.30 mg) (An unglycosylated rHu GM-CSF with isoleucine at position 100)		23rd October 1992
0223/0006	Seton Healthcare Group Plc	Mycota Spray	Undecenoic Acid BP 3.90% w/w Dichlorophen BP 0.40% w/w	Except POM cases: For the treatment and prevention of athlete's foot. GSL	1st October 1992
0223/0008	Seton Healthcare Group Plc	Mycota Powder	Zinc Undecenoate BP 20% w/w Undecenoic Acid BP 2% w/w	Except POM cases: For the treatment and prevention of athlete's foot. GSL	1st October 1992
0337/0205	Napp Laboratories Limited	Derbac-M Liquid	Malathion HSE 0.5% w/w	Except POM cases: Eradication of head lice, pubic lice and their eggs. Treatment of scabies. PM	29th October 1992
0337/0221	Napp Laboratories Limited	Adizem-SR Capsules 90 mg	Diltiazem Hydrochloride USP 90 mg		2nd October 1992
0337/0222	Napp Laboratories Limited	Adizem-SR Capsules 120 mg	Diltiazem Hydrochloride USP 120 mg		2nd October 1992
0337/0223	Napp Laboratories Limited	Adizem-SR Capsules 180 mg	Diltiazem Hydrochloride USP 180 mg		2nd October 1992
0337/0224	Napp Laboratories Limited	Adizem-XL Capsules 300 mg	Diltiazem Hydrochloride USP 300 mg		2nd October 1992
0338/0081	Cupcl Limited	Diasorb-Loperamide Capsules 2 mg	Loperamide Hydrochloride USP 2.000 mg	Except POM cases: Symptomatic relief of Acute Diarrhoea. PM	22nd October 1992
0339/0029	Radical Chemicals Limited (/v/a Fisons Consumer Health)	Cojone Tablets	Aspirin BP 300.00 mg Codeine Phosphate BP 8.00 mg Caffeine Citrate BPC 95.00 mg	Except POM cases: For use in overcoming rheumatic pains and for relief of headache, neuralgia, toothache, period pains and nerve pains, and to relieve symptoms of colds and influenza. PM	19th October 1992
0339/0030	Radical Chemicals Limited (/v/a Fisons Consumer Health)	Co-codamol EFF	Codeine Phosphate BP 8.0 mg Paracetamol BP 500.0 mg	Except POM cases: For the treatment of pain, including muscular and rheumatic pains, headache, migraine, neuralgia, toothache, sore throat, period pains, aches and pains, discomfort associated with influenza, feverishness and feverish colds. PM	19th October 1992
0339/0031	Radical Chemicals Limited (/v/a Fisons Consumer Health)	Cystopurin	Potassium Citrate BP 3 gm	Except POM cases: For the symptomatic relief of mild urinary tract infections (cystitis). PM	19th October 1992
0339/0032	Radical Chemicals Limited (/v/a Fisons Consumer Health)	Vapex Inhalant	Menthol BP 18.00% w/w	Except POM cases: For relief from colds and nasal catarrh. GSL	19th October 1992